ONC
BeiGene, Ltd. American Depositary Shares
About: Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Employees: 11,000
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
20% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $22.6M
10% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 31
4% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 75
0% more funds holding
Funds holding: 223 [Q3] → 223 (+0) [Q4]
0.22% less ownership
Funds ownership: 3.72% [Q3] → 3.49% (-0.22%) [Q4]
23% less capital invested
Capital invested by funds: $10.4B [Q3] → $8.06B (-$2.35B) [Q4]
40% less funds holding in top 10
Funds holding in top 10: 10 [Q3] → 6 (-4) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$312
35%
upside
Avg. target
$324
40%
upside
High target
$348
51%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Greg Renza 100% 1-year accuracy 1 / 1 met price target | 35%upside $312 | Outperform Initiated | 7 Apr 2025 |
Macquarie Tony Ren 0% 1-year accuracy 0 / 1 met price target | 36%upside $313 | Outperform Maintained | 28 Feb 2025 |
Citizens Capital Markets Matthew Carletti 67% 1-year accuracy 31 / 46 met price target | 51%upside $348 | Market Outperform Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 4 articles about ONC published over the past 30 days
Neutral
Business Wire
3 days ago
BeiGene to Announce First Quarter 2025 Financial Results on May 7
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investo.
Negative
Benzinga
2 weeks ago
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
BeiGene Ltd ONC on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.
Neutral
Business Wire
2 weeks ago
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre.
Neutral
Business Wire
2 weeks ago
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell l.
Positive
Benzinga
1 month ago
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
On Tuesday, BeiGene Ltd ONC announced FDA approval for Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1).
Neutral
Business Wire
1 month ago
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). “The approval of TEVI.
Positive
Seeking Alpha
1 month ago
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
BeiGene is a BUY due to Tevimbra's approval and Brukinsa's growing sales, leading to anticipated positive earnings in 2025. Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively, with a 78% and 55% increase, positioning BeiGene for profitability. BeiGene announced a name change to BeOne Medicines, transitioning from historical losses to profitability, and potentially attracting new buyers.
Neutral
24/7 Wall Street
1 month ago
The Billionaire Baker Brothers Just Made This Big Biotech Stock Move
If you're interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to.
Neutral
Zacks Investment Research
1 month ago
BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for BeiGene (ONC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neutral
Seeking Alpha
1 month ago
BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript
BeiGene, Ltd. (NASDAQ:ONC ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Dan Maller - Head, Investor Relations John Oyler - Co-Founder, Chairman & Chief Executive Officer Matt Shaulis - General Manager, North America Lai Wang - Global Head, R&D Aaron Rosenberg - Chief Financial Officer Conference Call Participants Kelly Shi - Jefferies Sean Laaman - Morgan Stanley & Co. Andrew Berens - Leerink Partners Jessica Fye - JPMorgan Yigal Nochomovitz - Citigroup Reni Benjamin - Citizens JMP Ziyi Chen - Goldman Sachs & Co Operator Good day, everyone.
Charts implemented using Lightweight Charts™